SecurityANY / Sphere 3D Corp. (84841L100)
Institutional Owners2
Institutional Shares18,131,000

Institutional Stock Ownership and Shareholders

Sphere 3D Corp. (NASDAQ:ANY) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 18,131,000 shares. Largest shareholders include Cyrus Capital Partners, L.p., and MacFarlane Family Ventures, LLC.

Sphere 3D Corp. (NASDAQ:ANY) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-11-16 13F-HR Cetera Investment Advisers 12,142 0 -100.00 2 0 -100.00
2017-11-14 13F-HR CLINTON GROUP INC 50,000 0 -100.00 10 0 -100.00
2017-11-14 13F-HR GROUP ONE TRADING, L.P. 53,578 0 -100.00 10 0 -100.00
2017-11-13 13F-HR CITIGROUP INC 1,000 0 -100.00 0 0
2017-11-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 24,109 0 -100.00 4 0 -100.00
2017-11-08 13F-HR CONDOR CAPITAL MANAGEMENT 16,330 0 -100.00 3 0 -100.00
2017-11-14 13F-HR UBS Group AG 2,009 0 -100.00 0 0
2017-11-14 13F-HR DEUTSCHE BANK AG\ 18 0 -100.00 0 0
2017-11-09 13F-HR WELLS FARGO & COMPANY/MN 5,000 0 -100.00 1 0 -100.00
2017-11-14 13F-HR SCOTIA CAPITAL INC. 37,500 0 -100.00 7 0 -100.00
2017-11-13 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 15,790 0 -100.00 3 0 -100.00
2017-11-03 13F-HR WESPAC Advisors SoCal, LLC 250 0 -100.00 0 0
2018-04-18 SC 13D/A CYRUS CAPITAL PARTNERS, L.P. 11,216,071 15,836,431 41.19
2017-10-30 13F-HR IFP Advisors, Inc 30,000 0 -100.00 6 0 -100.00
2017-11-13 13F-HR Marathon Capital Management 11,220 0 -100.00 2 0 -100.00
2017-11-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 109,567 0 -100.00 21 0 -100.00
2017-11-14 13F-HR MORGAN STANLEY 1,254,656 0 -100.00 242 0 -100.00
2018-03-30 SC 13D/A MacFarlane Family Ventures, LLC 1,994,570 2,294,569 15.04
2017-11-16 13F-HR Cetera Advisors LLC 12,142 0 -100.00 2 0 -100.00
2017-11-09 13F-HR CITADEL ADVISORS LLC 89,498 0 -100.00 17 0 -100.00
2017-11-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 81,800 0 -100.00 16 0 -100.00
2017-11-14 13F-HR CREDIT AGRICOLE S A 123 0 -100.00 0 0
2017-11-14 13F-HR TWO SIGMA SECURITIES, LLC 285,126 0 -100.00 54 0 -100.00
ANY: Sphere 3D Corp Analysis and Research Report

2018-04-09 - Asif

Overview Sphere 3D provides next-generation solutions for standalone storage and long-term data archive products, as well as technologies that converge the traditional silos of compute, storage and network into one integrated “hyper-converged” or converged solution. The company provide enterprise storage management solutions, the archiving of the data created by these solutions, and the ability to connect to public cloud services such as Microsoft Azure for additional delivery options and hybrid cloud capabilities. The company's solutions are tightly integrated and include a patented portfolio for operating systems for storage, proprietary virtual desktop orchestration software, and proprietary application container software. The company's software, combined with commodity x86 servers, or its purpose built appliances, deliver solutions that provide application mobility, security, data integrity and simplified management. These solutions can be deployed through a public, private...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 84841L100